Ascendis Pharma AS Cash Flow-to-Debt Ratio
Ascendis Pharma AS cash flow-to-debt ratio. Ascendis Pharma AS (ASND) has a Cash Flow-to-Debt Ratio of -0.01x as of March 2026, meaning its operating cash flow of $-7.85 Million could theoretically repay 0% of its total liabilities ($1.52 Billion) in one year. Check Ascendis Pharma AS (ASND) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Ascendis Pharma AS (2012–2025)
Cash flow-to-debt ratio of Ascendis Pharma AS from 2012 to 2025. Historical debt coverage capacity for Ascendis Pharma AS across 14 annual periods. Check ASND capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Ascendis Pharma AS Cash Flow-to-Debt Ratio by Year (2012–2025)
Ascendis Pharma AS cash flow-to-debt ratio by year from 2012 to 2025. Year-by-year debt coverage analysis for Ascendis Pharma AS. For the full cash flow conversion analysis, see Ascendis Pharma AS (ASND) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.04x | $51.77 Million | $1.46 Billion | ▲ +114.8% |
| 2024 | -0.24x | $-306.20 Million | $1.29 Billion | ▲ +50.5% |
| 2023 | -0.48x | $-467.36 Million | $971.28 Million | ▲ +19.8% |
| 2022 | -0.60x | $-495.70 Million | $826.39 Million | ▲ +71.1% |
| 2021 | -2.07x | $-417.65 Million | $201.29 Million | ▼ -7.8% |
| 2020 | -1.92x | $-271.55 Million | $141.08 Million | ▲ +12.9% |
| 2019 | -2.21x | $-175.94 Million | $79.62 Million | ▲ +38.0% |
| 2018 | -3.57x | $-138.80 Million | $38.92 Million | ▲ +10.9% |
| 2017 | -4.00x | $-95.10 Million | $23.77 Million | ▲ +10.5% |
| 2016 | -4.47x | $-60.18 Million | $13.46 Million | ▼ -17.7% |
| 2015 | -3.80x | $-43.47 Million | $11.45 Million | ▼ -165.4% |
| 2014 | -1.43x | $-18.40 Million | $12.86 Million | ▼ -562.6% |
| 2013 | 0.31x | $6.31 Million | $20.40 Million | ▲ +1231.5% |
| 2012 | -0.03x | $-652.00K | $23.85 Million | — |